Insights
Search Results
Client Highlights
5.11.26
Wilson Sonsini Advises Odyssey Therapeutics on Patent Matters Related to IPO
On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.
Alerts
5.07.26
Federal Circuit Provides Path to Written Description and Enablement for Patents Related to Methods of Using a Well-Known Class of Molecules
On April 16, 2026, the U.S. Court of Appeals for the Federal Circuit (the court) issued a precedential decision in Teva Pharmaceuticals International GmbH v. Eli Lily and Company, determining that the claims of Teva’s U.S. Patent Nos. 8,586,045 (the ’045 patent), 9,884,907 (the ’907 patent), and 9,884,908 (the ’908 patent) (collectively, the Headache Patents) relating to methods of reducing headache by administration of humanized anti-CGRP antagonist antibodies are not invalid for lack of written description or enablement. The decision reversed a district court’s judgment as a matter of law (JMOL) decision concluding otherwise, and reinstated the jury’s findings that Eli Lilly’s Emgality® product willfully infringed the Headache Patents.
News Articles
10.01.25
LMG Life Sciences Recognizes Wilson Sonsini, Attorneys in 2025 Guide
On September 30, 2025, LMG Life Sciences announced the 2025 edition of its guide, which identifies and ranks the leading law firms and individuals in the life sciences industry across the United States. The rankings are the result of firm participation in questionnaires, partner interviews to gather market feedback, client surveys, and independent research. LMG Life Sciences has conducted research and published rankings since 2012. This year, six Wilson Sonsini practices and 18 attorneys have been recognized in the guide.
News Articles
9.04.25
Derrick Rowe Honored Among The National Law Journal’s 2025 D.C. Rising Stars
On September 4, 2025, Wilson Sonsini partner Derrick Rowe was selected among the honorees for “D.C. Rising Stars” during The National Law Journal Legal Awards, which highlight the top work in Washington, D.C. This year’s honorees have wielded influence in their practice areas in the D.C. area and beyond. All of the honorees and finalists will be celebrated at an awards dinner in D.C. on November 5.
Alerts
9.04.25
Inventor’s Failure to Provide Material Information to the USPTO Results in an Unenforceable Patent
On August 20, 2025, the U.S. District Court for the District of Delaware (court) found inequitable conduct when Applicant, Lindis Biotech, GMBH (Lindis), relied on data from hastily performed experiments to obtain a patent from the United States Patent and Trademark Office (USPTO), while withholding from the USPTO more thorough contradictory data.
Alerts
5.01.25
Method of Treatment Claim’s Limiting Preamble Must Satisfy the Written Description Requirement
On March 13, 2025, the U.S. Court of Appeals for the Federal Circuit issued a decision in the case of In Re: Xencor, Inc.1 In this Appeal from the Appeals Review Panel of the Patent Trial and Appeal Board (ARP), with regard to U.S. Application No. 16/803,690 (’690 application), the court held that the preamble of the method of treatment claims at issue is limiting, and thus requires sufficient written description under 35 U.S.C. §112.